Development of MEDI4736, an anti-programmed cell death ligand 1 (PD-L1) antibody, as monotherapy or in combination with other therapies in the treatment of non-small cell lung cancer (NSCLC). (6th November 2014)

Record Type:: Journal Article
Title:: Development of MEDI4736, an anti-programmed cell death ligand 1 (PD-L1) antibody, as monotherapy or in combination with other therapies in the treatment of non-small cell lung cancer (NSCLC). (6th November 2014)
Main Title:: Development of MEDI4736, an anti-programmed cell death ligand 1 (PD-L1) antibody, as monotherapy or in combination with other therapies in the treatment of non-small cell lung cancer (NSCLC)
Authors:: Brahmer, Julie
Balmanoukian, Ani
Goldberg, Sarah
Ou, Sai-Hong
Blake-Haskins, Andrew
Karakunnel, Joyson
Stockman, Paul
Rizvi, Naiyer
Antonia, Scott
Abstract:
Is Part Of:: Journal for immunotherapy of cancer. Volume 2(2014)Supplement 3
Journal:: Journal for immunotherapy of cancer
Issue:: Volume 2(2014)Supplement 3
Issue Display:: Volume 2, Issue 3 (2014)
Year:: 2014
Volume:: 2
Issue:: 3
Issue Sort Value:: 2014-0002-0003-0000
Page Start:
Page End:
Publication Date:: 2014-11-06
Subjects:: Amylase -- Gefitinib -- Disease Control Rate -- Death Ligand -- Epigastric Discomfort
Cancer -- Immunotherapy -- Periodicals
Cancer -- Immunological aspects -- Periodicals
Tumors -- Immunological aspects -- Periodicals
Immunotherapy -- Periodicals
616.99406105
Journal URLs:: http://www.immunotherapyofcancer.org ↗
https://jitc.bmj.com/ ↗
http://link.springer.com/ ↗
DOI:: 10.1186/2051-1426-2-S3-P179 ↗
Languages:: English
ISSNs:: 2051-1426
Deposit Type:: Legaldeposit
View Content:: Available online (eLD content is only available in our Reading Rooms) ↗
Physical Locations:: British Library DSC - BLDSS-3PM
British Library HMNTS - ELD Digital store
Ingest File:: 19212.xml